Latest Breaking News On - Exaci chief business officer - Page 1 : comparemela.com

Eterna Therapeutics (ERNA) Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Eterna Therapeutics (ERNA) Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dimitrios goundisGregory fioreExacis biotherapeuticsMatt angelMaxivax sa eternaHead of researchExchange commissionMedicines companySecurities exchangeEterna therapeutics incWith exaciChief executive officerAeterna boardExaci chief business officerExaci scientific advisory boardEterna therapeuticseterna therapeutics

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomDimitrios goundisExacis biotherapeuticsMaxivax sa eternaMatt angelGregory fioreEterna therapeutics incMedicines companyExchange commissionSecurities exchangeHead of researchWall streetWith exaciChief executive officerAeterna boardExaci chief business officer

EXACIS BIOTHERAPEUTICS GRANTS ETERNA THERAPEUTICS AN OPTION TO LICENSE UP TO FOUR ALLOGENEIC IPSC-DERIVED NK AND T CELL THERAPIES

/PRNewswire/ Exacis Biotherapeutics Inc. ("Exacis" or the "Company"), a development-stage immuno-oncology company working to harness the immune system to.

United kingdomDimitri goundisMatt angelEterna therapeutics incExacis biotherapeutics incEterna therapeuticsExaci chief business officerInterim chief executive officerExacis biotherapeutics inc